Wrinkle AppearanceNCT07446361
A Study to Evaluate the Efficacy of Collagen 16 Serum Alone, Against and as an Adjunct to Radiesse® Biostimulation Procedure in Female Trial Participants With Aged Skin
A study testing Group 1 (Biostimulation + Test product) and Group 3 (Test product Alone) in people with Wrinkle Appearance and Skin Quality, run by Vichy Laboratoires.
Trial summary
This study aims at assessing the efficacy of improving skin aging signs of a serum containing collagen 16 combined with a biostimulation device in healthy female subjects aged between 30 and 70 years over a period of 13 weeks. Read more about this study
- Who is it for?
- Ages 30 to 70 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Wrinkle Appearance, Skin Quality
- What is being tested?
- Group 1 (Biostimulation + Test product) and Group 3 (Test product Alone)
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 180 participants
- Where
- No sites listed yet
- Study dates
- 1 Mar 2026to Sep 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 70 years
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Female trial participants aged from 30 to 70 years.
- Trial participants who are regular users of anti-aging cosmetic products.
- Trial participants presenting with:
- Wrinkle visibility score ≥3 and ≤6 on a 10-point visual scale.
- Fine lines visibility score ≥3 and ≤6 on a 10-point visual scale.
- Crow's feet wrinkle score ≥2 and ≤4 on the L'Oréal Atlas (volume 1 caucasian type).
- Skin radiance score ≥3 and ≤6 on a 10-point visual scale.
- Plumpness score ≥3 and ≤6 on a 10-point visual scale
Who cannot join
- Trial participants who are pregnant, breastfeeding, or planning to become pregnant during the study period.
- Trial participants who are currently participating in another facial clinical study or who have participated in such a study within 1 month that may interfere with the study outcomes.
- Trial participants presenting with current flaring or severe inflammatory acne or any active dermatological condition that, in the investigator's opinion, could interfere with study assessments.
- Trial participants who have undergone ablative laser treatments, microneedling, chemical peels, dermabrasion, non-ablative laser, intense pulsed light (IPL), or injectable procedures within the last 12 months from the day of screening.
- Trial participants who have undergone biostimulation procedures in the past 6 to 9 months from the day of screening
- Trial participants with a known allergy to any component of the investigational product(s), comparator product(s), or additional products used in the study.
Show all 11Show fewer
- Trial participants presenting with any medical or dermatological condition that, in the investigator's opinion, may compromise trial participant safety or interfere with study conduct or evaluation.
- Trial participants who are unable or unwilling to comply with the study requirements and instructions.
- Trial participants who are unable to provide written informed consent.
- Trial participant with clinically significant history of alcoholism or drug abuse;
- Trial participant who are employees of MSCR or Sponsor
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: A Randomized Clinical Study to Evaluate the Efficacy of Collagen 16 Serum Alone, Against and as an Adjunct to Radiesse® Biostimulation Procedure in Female Trial Participants With Aged Skin
This study aims at assessing the efficacy of improving skin aging signs of a serum containing collagen 16 combined with a biostimulation device in healthy female subjects aged between 30 and 70 years over a period of 13 weeks.
- Conditions
- Wrinkle Appearance, Skin Quality
- Being tested
- Group 1 (Biostimulation + Test product), Group 2 (Biostimulation + Placebo), Group 3 (Test product Alone)
- Keywords
- anti-aging, cosmetics, collagen 16, biostimulation, placebo serum
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Group 1 (Biostimulation + Test product)Other
- Facial wrinkles, assessed by clinical scoring using the L'Oréal Atlas (volume 1 caucasian type), based on changes from baseline to Week 13.
Clinical evaluations, including:
- Crow's feet wrinkles (0-6)
- Nasolabial folds (0-5)
- Underneath eye wrinkles (0-5)
- Upper lip wrinkles (0-6)
- Wrinkles at the corner of the lips (0-6)
Clinical evaluations, including:
- Global wrinkles (visual assessment)
- Fine lines (visual assessment)
- Skin firmness (tactile assessment)
- Skin elasticity (tactile assessment)
- Skin tone evenness (visual assessment)
- Skin radiance (visual assessment)
- Skin smoothness (visual assessment)
- Ptosis of the lower part of the face (visual assessment)
- Plumpness (visual assessment)
Instrumental measurements, including:
- Dermis density (SIAscope)
- Transepidermal water loss (TEWL) (Tewameter)
- Skin hydration (Corneometer)
- VISIA CR imaging
To evaluate trial participant self-perceived efficacy using questionnaires.
To assess the local tolerance and safety
Group 2 (Biostimulation + Placebo)Other
- Facial wrinkles, assessed by clinical scoring using the L'Oréal Atlas (volume 1 caucasian type), based on changes from baseline to Week 13.
Clinical evaluations, including:
- Crow's feet wrinkles (0-6)
- Nasolabial folds (0-5)
- Underneath eye wrinkles (0-5)
- Upper lip wrinkles (0-6)
- Wrinkles at the corner of the lips (0-6)
Clinical evaluations, including:
- Global wrinkles (visual assessment)
- Fine lines (visual assessment)
- Skin firmness (tactile assessment)
- Skin elasticity (tactile assessment)
- Skin tone evenness (visual assessment)
- Skin radiance (visual assessment)
- Skin smoothness (visual assessment)
- Ptosis of the lower part of the face (visual assessment)
- Plumpness (visual assessment)
Instrumental measurements, including:
- Dermis density (SIAscope)
- Transepidermal water loss (TEWL) (Tewameter)
- Skin hydration (Corneometer)
- VISIA CR imaging
To evaluate trial participant self-perceived efficacy using questionnaires.
To assess the local tolerance and safety
Group 3 (Test product Alone)Other
- Facial wrinkles, assessed by clinical scoring using the L'Oréal Atlas (volume 1 caucasian type), based on changes from baseline to Week 13.
Clinical evaluations, including:
- Crow's feet wrinkles (0-6)
- Nasolabial folds (0-5)
- Underneath eye wrink
Clinical evaluations, including:
- Global wrinkles (visual assessment)
- Fine lines (visual assessment)
- Skin firmness (tactile assessment)
- Skin elasticity (tactile assessment)
- Skin tone evenness (visual assessment)
- Skin radiance (visual assessment)
- Skin smoothness (visual assessment)
- Ptosis of the lower part of the face (visual assessment)
- Plumpness (visual assessment)
Instrumental measurements, including:
- Dermis density (SIAscope)
- Transepidermal water loss (TEWL) (Tewameter)
- Skin hydration (Corneometer)
- VISIA CR imaging
To evaluate trial participant self-perceived efficacy using questionnaires.
To assess the local tolerance and safety of the investigational and comparator
| Study group | Role | What they receive |
|---|---|---|
| Group 1 (Biostimulation + Test product) | Experimental | * application of collagen 16 serum (morning and evening)
* Capital Soleil Family Milk SPF 30 (morning)
* La Roche-Posay Hydraphase Light (evening)
* Biostimulation injection at Visit 2 Receives: Other: Group 1 (Biostimulation + Test product) |
| Group 2 (Biostimulation + Placebo) | Placebo comparator | Not described Receives: Other: Group 2 (Biostimulation + Placebo) |
| Group 3 (Test product Alone) | Active comparator | Not described Receives: Other: Group 3 (Test product Alone) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Facial wrinkle score on the L'Oreal Skin Atlas (Caucasian type) scale ranging from 0=none to 9=very visible wrinkle
wrinkles will be visually assessed on the whole face by the investigator on a scale from 0= no visible wrinkle to 9=very visible wrinkle
Measured: at baseline, week 3, week 7 and week 13
Secondary outcomes (15)
Global wrinkles score on the L'Oreal Skin Atlas (Caucasian type) ranging from 0=none to 9=very visible wrinkle
global wrinkles will be visually assessed on the whole face by the investigator on a scale from 0= no visible wrinkle to 9=very visible wrinkle
Measured: at baseline, week 3, week 7 and week 13
Fine lines score on the L'Oreal Skin Atlas (Caucasian type) ranging from 0=none to 9=very visible fine lines
fine lines will be visually assessed on yhe whole face by the investigator on a scale from 0= no visible fine lines to 9=very visible fine lines
Measured: at baseline, week 3, week 7 and week 13
Skin firmness score on the L'Oreal Skin Atlas (Caucasian type) ranging from 0=very firm skin to 9=very saggy/not firm skin
skin firmness will be assessed (tactile) on a scale from 0=very firm skin to 9= very saggy/not firm skin
Measured: at baseline, week 3, week 7 and week 13
Skin elasticity on the L'Oreal Skin Atlas (Caucasian type) ranging from 0=very elastic to 9=very loos/not elastic skin
skin elasticity will be assessed (tactil) by the investigator on a scale from 0=very elastic scale to 9=very loos/not elastic skin
Measured: at baseline, week 3, week 7 and week 13
Skin tone evenness on the L'Oreal Skin Atlas (Caucasian type) ranging from 0=very even skin tone to 9=uneven skin tone
skin tone eveness will be visually assessed by the investigator on scale from 0=very even skin tone to 9= uneven skin tone
Measured: at baseline, week 3, week 7 and week 13
Skin radiance on the L'Oreal Skin Atlas (Caucasian type) ranging from 0=very radiant complexion to 9=very uneven complexion/dull complexion
skin radiance will be visually assessed by the investigator on a scale from 0=very radiant complexion to 9=very uneven complexion/dull complexion
Measured: at baseline, week 3, week 7 and week 13
Skin smoothness on the L'Oreal Skin Atlas (Caucasian type) ranging from 0=very smooth skin texture to 9=very rough skin texture
skin smoothness will be visually assessed by the investigator on a scale from 0= very smooth skin texture to 9=very rough skin texture
Measured: at baseline, week 3, week 7 and week 13
Ptosis of the lower part of the face on the L'Oreal Skin Atlas (Caucasian type) ranging from 0=no sagging skin to 9=very sagging skin
ptosis (skin sagginess) on the lower face will be visually assessed by the investigator on a scale from 0= no sagging skin (defined contours) to 9=very sagging skin (not defined contours)
Measured: at baseline, week 3, week 7 and week 13
Plumpness on the L'Oreal Skin Atlas (Caucasian type) scale ranging from 0=very plumped skin to 9=not plumped skin
plumpness will be visually assessed by the investigator on the entire face on a scale from 0= very plumped skin to 9=not plumped skin
Measured: at baseline, week 3, week 7 and week 13
Dermis density using SIAscope (Spectophotometric intracutaneous analysis; arbitrary units)
Dermis density will be measured using SIAscope (randomized to left or right temple)
Measured: at baseline, week 3, week 7 and week 13
Transepidermal waterloss using a tewameter (g/m2/h)
transepidermal water loss will be measured using a tewameter
Measured: at baseline, week 3, week 7 and week 13
Skin hydration using a corneometer (arbitary unit)
skin hydration will be measured using a corneometer
Measured: at baseline, week 3, week 7 and week 13
Standardised imaging of the face using Visia CR imaging (no unit)
Standardised imaging of the face will be performed using Visia CR
Measured: at baseline, week 3, week 7 and week 13
Integrative health questionnaire (23 questions) developped for this study
an integrative health questionnaire will be completed by subjects 7 days before inclusion
Measured: Day -7 (7 days before baseline)
Safety assessment including local side effects and any adverse event reported by the subject during the course of the study
Evaluation of local tolerance and any adverse event by investigator and trial participants
Measured: baseline, week 3, week 7 and week 13
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Mar 2026
- Study start1 Mar 2026 (estimated)
- Primary completionAug 2026 (estimated)
- Study completionSep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Wrinkle AppearanceStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- randomized, controlled, parallel-group design with independent assessor blinding
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 180 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Vichy Laboratoires
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07446361
- Sponsor's protocol ID
- VCY25-010
- Status last verified
- Feb 2026
- First submitted
- 13 Feb 2026
- Last updated
- 3 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized Clinical Study to Evaluate the Efficacy of Collagen 16 Serum Alone, Against and as an Adjunct to Radiesse® Biostimulation Procedure in Female Trial Participants With Aged Skin
- ClinicalTrials.gov ID
- NCT07446361
- Acronym / sponsor ID
- VCY25-010
- Conditions
- Wrinkle Appearance, Skin Quality
- Keywords
- anti-aging, cosmetics, collagen 16, biostimulation, placebo serum
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 180 participants (estimated)
- Lead sponsor
- Vichy LaboratoiresIndustry (pharma, biotech, devices)
- Study start
- 1 Mar 2026 (estimated)
- Primary completion
- Aug 2026 (estimated)
- Study completion
- Sep 2026 (estimated)
- First posted
- 3 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims at assessing the efficacy of improving skin aging signs of a serum containing collagen 16 combined with a biostimulation device in healthy female subjects aged between 30 and 70 years over a period of 13 weeks.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 3
- Model description
- randomized, controlled, parallel-group design with independent assessor blinding
| Arm | Type | Receives |
|---|---|---|
| Group 1 (Biostimulation + Test product) | Experimental | Other: Group 1 (Biostimulation + Test product)* application of collagen 16 serum (morning and evening) * Capital Soleil Family Milk SPF 30 (morning) * La Roche-Posay Hydraphase Light (evening) * Biostimulation injection at Visit 2 |
| Group 2 (Biostimulation + Placebo) | Placebo comparator | Other: Group 2 (Biostimulation + Placebo) |
| Group 3 (Test product Alone) | Active comparator | Other: Group 3 (Test product Alone) |
Who may qualify
- Ages
- 30 to 70 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Female trial participants aged from 30 to 70 years.
- Trial participants who are regular users of anti-aging cosmetic products.
- Trial participants presenting with:
- Wrinkle visibility score ≥3 and ≤6 on a 10-point visual scale.
- Fine lines visibility score ≥3 and ≤6 on a 10-point visual scale.
Key exclusion criteria (11 listed)
- Trial participants who are pregnant, breastfeeding, or planning to become pregnant during the study period.
- Trial participants who are currently participating in another facial clinical study or who have participated in such a study within 1 month that may interfere with the study outcomes.
- Trial participants presenting with current flaring or severe inflammatory acne or any active dermatological condition that, in the investigator's opinion, could interfere with study assessments.
- Trial participants who have undergone ablative laser treatments, microneedling, chemical peels, dermabrasion, non-ablative laser, intense pulsed light (IPL), or injectable procedures within the last 12 months from the day of screening.
- Trial participants who have undergone biostimulation procedures in the past 6 to 9 months from the day of screening
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Group 1 (Biostimulation + Test product)• Facial wrinkles, assessed by clinical scoring using the L'Oréal Atlas (volume 1 caucasian type), based on changes from baseline to Week 13. Clinical evaluations, including: * Crow's feet wrinkles (0-6) * Nasolabial folds (0-5) * Underneath eye wrinkles (0-5) * Upper lip wrinkles (0-6) * Wrinkles at the corner of the lips (0-6) Clinical evaluations, including: * Global wrinkles (visual assessment) * Fine lines (visual assessment) * Skin firmness (tactile assessment) * Skin elasticity (tactile assessment) * Skin tone evenness (visual assessment) * Skin radiance (visual assessment) * Skin smoothness (visual assessment) * Ptosis of the lower part of the face (visual assessment) * Plumpness (visual assessment) Instrumental measurements, including: * Dermis density (SIAscope) * Transepidermal water loss (TEWL) (Tewameter) * Skin hydration (Corneometer) * VISIA CR imaging To evaluate trial participant self-perceived efficacy using questionnaires. To assess the local tolerance and safety | Other | Group 1 (Biostimulation + Test product) |
| Group 2 (Biostimulation + Placebo)• Facial wrinkles, assessed by clinical scoring using the L'Oréal Atlas (volume 1 caucasian type), based on changes from baseline to Week 13. Clinical evaluations, including: * Crow's feet wrinkles (0-6) * Nasolabial folds (0-5) * Underneath eye wrinkles (0-5) * Upper lip wrinkles (0-6) * Wrinkles at the corner of the lips (0-6) Clinical evaluations, including: * Global wrinkles (visual assessment) * Fine lines (visual assessment) * Skin firmness (tactile assessment) * Skin elasticity (tactile assessment) * Skin tone evenness (visual assessment) * Skin radiance (visual assessment) * Skin smoothness (visual assessment) * Ptosis of the lower part of the face (visual assessment) * Plumpness (visual assessment) Instrumental measurements, including: * Dermis density (SIAscope) * Transepidermal water loss (TEWL) (Tewameter) * Skin hydration (Corneometer) * VISIA CR imaging To evaluate trial participant self-perceived efficacy using questionnaires. To assess the local tolerance and safety | Other | Group 2 (Biostimulation + Placebo) |
| Group 3 (Test product Alone)• Facial wrinkles, assessed by clinical scoring using the L'Oréal Atlas (volume 1 caucasian type), based on changes from baseline to Week 13. Clinical evaluations, including: * Crow's feet wrinkles (0-6) * Nasolabial folds (0-5) * Underneath eye wrink Clinical evaluations, including: * Global wrinkles (visual assessment) * Fine lines (visual assessment) * Skin firmness (tactile assessment) * Skin elasticity (tactile assessment) * Skin tone evenness (visual assessment) * Skin radiance (visual assessment) * Skin smoothness (visual assessment) * Ptosis of the lower part of the face (visual assessment) * Plumpness (visual assessment) Instrumental measurements, including: * Dermis density (SIAscope) * Transepidermal water loss (TEWL) (Tewameter) * Skin hydration (Corneometer) * VISIA CR imaging To evaluate trial participant self-perceived efficacy using questionnaires. To assess the local tolerance and safety of the investigational and comparator | Other | Group 3 (Test product Alone) |
Primary outcome
Facial wrinkle score on the L'Oreal Skin Atlas (Caucasian type) scale ranging from 0=none to 9=very visible wrinkle
Time frame: at baseline, week 3, week 7 and week 13
wrinkles will be visually assessed on the whole face by the investigator on a scale from 0= no visible wrinkle to 9=very visible wrinkle
15 secondary outcomes
Global wrinkles score on the L'Oreal Skin Atlas (Caucasian type) ranging from 0=none to 9=very visible wrinkle
Time frame: at baseline, week 3, week 7 and week 13
Fine lines score on the L'Oreal Skin Atlas (Caucasian type) ranging from 0=none to 9=very visible fine lines
Time frame: at baseline, week 3, week 7 and week 13
Skin firmness score on the L'Oreal Skin Atlas (Caucasian type) ranging from 0=very firm skin to 9=very saggy/not firm skin
Time frame: at baseline, week 3, week 7 and week 13
Skin elasticity on the L'Oreal Skin Atlas (Caucasian type) ranging from 0=very elastic to 9=very loos/not elastic skin
Time frame: at baseline, week 3, week 7 and week 13
Skin tone evenness on the L'Oreal Skin Atlas (Caucasian type) ranging from 0=very even skin tone to 9=uneven skin tone
Time frame: at baseline, week 3, week 7 and week 13
Skin radiance on the L'Oreal Skin Atlas (Caucasian type) ranging from 0=very radiant complexion to 9=very uneven complexion/dull complexion
Time frame: at baseline, week 3, week 7 and week 13
Skin smoothness on the L'Oreal Skin Atlas (Caucasian type) ranging from 0=very smooth skin texture to 9=very rough skin texture
Time frame: at baseline, week 3, week 7 and week 13
Ptosis of the lower part of the face on the L'Oreal Skin Atlas (Caucasian type) ranging from 0=no sagging skin to 9=very sagging skin
Time frame: at baseline, week 3, week 7 and week 13
Plumpness on the L'Oreal Skin Atlas (Caucasian type) scale ranging from 0=very plumped skin to 9=not plumped skin
Time frame: at baseline, week 3, week 7 and week 13
Dermis density using SIAscope (Spectophotometric intracutaneous analysis; arbitrary units)
Time frame: at baseline, week 3, week 7 and week 13
Transepidermal waterloss using a tewameter (g/m2/h)
Time frame: at baseline, week 3, week 7 and week 13
Skin hydration using a corneometer (arbitary unit)
Time frame: at baseline, week 3, week 7 and week 13
Standardised imaging of the face using Visia CR imaging (no unit)
Time frame: at baseline, week 3, week 7 and week 13
Integrative health questionnaire (23 questions) developped for this study
Time frame: Day -7 (7 days before baseline)
Safety assessment including local side effects and any adverse event reported by the subject during the course of the study
Time frame: baseline, week 3, week 7 and week 13
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for Wrinkle Appearance
Recruiting
Clinical Evaluation of a Multi-functional Beauty Device on Cosmetic Skin Outcomes
Skin Appearance, Skin Texture
RecruitingPhase 3
A Study to Assess the Effectiveness and Safety of IPN10200 in Adult Chinese Participants With Moderate to Severe Wrinkle-like Lines Between the Eyebrows
Moderate to Severe Glabellar Lines
Not yet recruitingObservational study
Comparing Facial Aging Between Identical Twins With 3D Imaging
Facial Skin Aging, Facial Volume Loss
Recruiting
Effect of Single Facial Acupuncture on Dermal Structure and Appearance Satisfaction
Facial Aging, Wrinkles
RecruitingPhase 1/2
Autologous Adipose Cells Therapy
Hair Loss/Baldness, Wrinkle Appearance
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A study testing Group 1 (Biostimulation + Test product) and Group 3 (Test product Alone) in people with Wrinkle Appearance and Skin Quality, run by Vichy Laboratoires.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 3 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Claire Deloche-Bensmain, PhD (0033776112798, Claire.DELOCHE-BENSMAINE@loreal.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Facial wrinkle score on the L'Oreal Skin Atlas (Caucasian type) scale ranging from 0=none to 9=very visible wrinkle (time frame: at baseline, week 3, week 7 and week 13). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Mar 2026.